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Scope: To develop a physiologically based kinetic (PBK) model that describes the absorption,
distribution, metabolism, and excretion of hesperidin in humans, enabling the translation of
in vitro concentration–response curves to in vivo dose–response curves.
Methods and results: The PBK model for hesperidin in humans was developed based on
in vitro metabolic parameters. Hesperidin was predicted to mainly occur in the systemic
circulation as different monoglucuronides. The plasma concentrations of hesperidin aglycone
(hesperetin) was predicted to be <0.02 mg/L at an oral dose of 50 mg/kg bw. The developed
PBKmodel allowed conversion of in vitro concentration–response curves for different effects to
in vivo dose–response curves. The BMD05 (benchmark dose for 5% response) values for protein
kinase A inhibition ranged between 135 and 529 mg/kg bw hesperidin, and for inhibition of
endothelial cell migration and prostaglandin E2 and nitric oxide production ranged between
2.19 and 44 mg/kg bw hesperidin. These values are in line with reported human data showing
in vivo effects by hesperidin and show that these effects may occur at Western dietary and
supplementary intake of hesperidin.
Conclusions: The developed PBK model adequately predicts absorption, distribution,
metabolism, and excretion of hesperidin in humans and allows to evaluate the human in
vivo situation without the need for human intervention studies.
Keywords:
ADME / Hesperetin metabolites / Hesperidin / In vitro–in vivo extrapolation / PBK
modeling
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
1 Introduction
Hesperidin (hesperetin-7-O-rutinoside) is the -glycoside
form of the flavanone hesperetin, and is almost exclusively
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Abbreviations: ADME, absorption, distribution, metabolism,
and excretion; Cmax, maximum concentration; ECin vitro or in vivo,
effective in vitro or in vivo concentration; GI, gastrointesti-
nal; H-7G, hesperetin-7-O-glucuronide; H-3′G, hesperetin-3′-O-
glucuronide; H-3′S, hesperetin-3′-O-sulfate; H-3′7diG, hesperetin-
3′,7-O-diglucuronide; H-7G-3′S, hesperetin-7-O-glucuronide-3′-
O-sulfate; NO, nitric oxide; PAPS, 3′-phosphoadenosine 5′-
phosphosulfate; PBK, physiologically based kinetic; PGE2,
prostaglandin E2; PKA, protein kinase A; SC, sensitivity coeffi-
cient; UDPGA, uridine 5′-diphosphoglucuronide acid
present in citrus fruits, especially in orange [1]. Sweet orange
juice contains 487–584 mg hesperidin/L [2]. Hesperidin and
its aglycone, hesperetin, have been suggested to exert various
beneficial health effects against many degenerative diseases
including cancer, cardiovascular diseases, osteoporosis, obe-
sity, and diabetes [3–5]. In addition also beneficial health ef-
fects have been reported for hesperetin metabolites based on
their interaction with various key proteins such as protein
kinases [6–9] and via induction or reduction of specific genes
related to cellular functions [10–12]. During uptake follow-
ing oral ingestion, hesperidin and its aglycone hesperetin are
extensively metabolized in intestinal and liver tissue and as
a result hesperetin is mostly present in the systemic circu-
lation in conjugated forms [13–16]. This raises the question
∗Current address: Ans Punt, RIKILT—Wageningen University &
Research Wageningen, The Netherlands.
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of whether any in vivo biological effect of hesperidin or hes-
peretin is due to the free aglycone hesperetin or perhaps, at
least in part, to thesemetabolites. Little is known about physi-
ologically relevant concentrations of hesperetin aglycone and
its circulating metabolites in vivo. For a better translation of
in vitro results to in vivo effects, it is of importance to gain
more insight in absorption, distribution, metabolism, and ex-
cretion (ADME) of hesperidin upon ingestion, especially to
obtain an indication of the physiologically relevant plasma
concentrations of hesperetin aglycone and its circulating
metabolites.
Dietary intake of hesperidin in Western countries is
estimated to be 193–562 mg hesperidin corresponding to
2.8–8 mg/kg bw for a 70 kg person [17]. Hesperidin is also
available as a food supplement with daily doses of 500–2000
mg hesperidin corresponding to 7–29 mg/kg bw for a 70
kg person [18]. Figure 1 illustrates the proposed metabolic
pathways of dietary hesperidin in humans. Upon oral inges-
tion, hesperidin cannot be hydrolyzed by -glucosidases in
the small intestine, but passes to the colon, where it can
be hydrolyzed to hesperetin aglycone by colonic microbiota
prior to its absorption into the colonic enterocyte [14]. The
release of hesperetin is the rate-limited step for absorption
[16]. In contrast to hesperidin, hesperetin aglycone can be
directly taken up in the small intestinal enterocyte by pas-
sive diffusion [14]. The absorbed hesperetin is metabolized
by UDP-glucuronosyl transferases and sulfotransferases in
the colon, small intestine, and liver at the 3′- and 7-position
[19]. Several metabolites of hesperetin including mono- and
diconjugates have been identified in human urine, indicating
further conjugation of monoconjugates [13, 15, 20].
To better understand in vivo effects of dietary hesperidin,
the present study aimed to develop a physiologically based
kinetic (PBK) model for hesperidin to gain insight in dose-
dependent plasma concentrations of hesperetin aglycone
and its metabolites. The developed PBK model was subse-
quently combined with in vitro effect data using a so-called
reverse dosimetry approach to determine whether in vitro ef-
fects of hesperetin and its metabolites can also be expected
to occur in vivo, and if so, at what hesperidin oral dose
levels.
2 Materials and methods
2.1 Materials
Pooled mixed-gender human tissue fractions including
small intestine microsomes, small intestine cytosol, liver
microsomes, liver cytosol, and individual male colon S9
were purchased from Xenotech (Lenexa, USA). Uridine
5′-diphosphoglucuronide acid (UDPGA, purity 98%), 3′-
phosphoadenosine 5′-phosphosulfate (PAPS, purity 65%),
Tris, alamethicin (from Trichoderma viride), D-saccharic acid
1,4-lactone monohydrate, and DTT were purchased from
Sigma-Aldrich (Steinheim, Germany). Hydrochloric acid
(fuming 37%), magnesium chloride, TFA (for spectroscopy),
potassium dihydrogen phosphate, dipotassium hydrogen
phosphate trihydrate, and DMSOwere purchased from VWR
International (Darmstadt, Germany). ACN (chromatogra-
phy grade) was purchased from Biosolve (Valkenswaard,
The Netherlands). Hesperetin (>99%) was purchased
from Extrasynthese (Genay Cedex, France). Hesperetin-7-O-
glucuronide (H-7G) was purchased from Toronto Research
Chemicals (Toronto, Canada). Hesperetin-3′-O-glucuronide
(H-3′G) andhesperetin-3′,7-O-diglucuronide (H-3′7diG)were
purchased from Apollo Scientific (Cheshire, UK). Recom-
binant human cAMP-dependent protein kinase, catalytic
subunit C (PKA-C), kemptide (LRRASLG), ATP, and
staurosporine were purchased from Biaffin (Kassel, Ger-
many). ADP was purchased from DiscoveRx (Birmingham,
UK).
Figure 1. Proposed metabolic pathways of dietary hes-
peridin and hesperetin in humans: glucuronide (G) and
sulfate (S) [13,15,20].
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2.2 Enzymatic conjugation of H-7G and H-3′G with
pooled human tissue fractions
To obtain kinetic parameters for glucuronidation and sulfa-
tion of the monoconjugates, H-7G and H-3′G, to diconju-
gates, in vitro incubations with human tissue fractions were
performed according to themethods described by Brand et al.
[19] with somemodifications. For glucuronidation, 100L in-
cubationmixtures were prepared containing (final concentra-
tions) 10 mM MgCl2, 10 mM UDPGA, 0.025 mg/mL alame-
thicin (added from a 200 times concentrated stock solution in
methanol), and human tissue fractions in 50 mM Tris-HCl
(pH 7.4). For incubations with H-7G, a protein content of
0.6 mg/mL small intestine microsomes, 0.6 mg/mL liver
microsomes, or 0.8 mg/mL colon S9 and incubation times
of 4, 2, or 6 h were applied. For incubations with H-3′G, a
protein content of 0.3 mg/mL small intestine microsomes,
1.0 mg/mL liver microsomes, or 0.8 mg/mL colon S9 and
incubation times of 4, 3, or 6 h were applied. The reactions
were initiated by adding H-7G or H-3′G from 200 times stock
solutions in DMSO (final concentration of the substrate rang-
ing from 5 to 400 M) and were terminated by adding 25 L
of ice-cold ACN. Blank incubations were carried out with-
outUDPGA.Under the specified conditions, glucuronidation
was linear with time and protein content (data not shown).
For sulfation, 100 L incubation mixtures were prepared
containing (final concentrations) 5 mM MgCl2, 0.1 mM
PAPS, 20 mM saccharic acid-1,4-lactone (pH 7.4) as -
glucuronidase inhibitor [21], and human tissue fractions in
50 mM potassium phosphate (pH 7.4). For incubations with
H-7G, a protein content of 0.8mg/mL small intestine cytosol,
liver cytosol, or colon S9 and incubation times of 3, 4, or 6 h
were applied. For incubations with H-3′G, a protein content
of 0.8 mg/mL small intestine cytosol, liver cytosol, or colon
S9 and incubation times of 5, 4, or 6 h were applied. The reac-
tions were initiated by adding H-7G or H-3′G from 200 times
stock solutions in DMSO (final concentration of the substrate
ranging from 5 to 400 M) and were terminated by adding
25 L of ice-cold ACN. Blank incubations were carried out
without PAPS. Under the specified conditions, sulfation was
linear with time and protein content (data not shown).
2.3 Identification and quantification of hesperetin
metabolites
All incubation samples were analyzed on a UPLC-DAD sys-
tem consisting of a Waters (Milford, MA) Acquity binary sol-
vent manager, sample manager, and photodiode array detec-
tor, equipped with a Waters Acquity UPLC BEH C18 column
(1.7 m, 2.1 × 50 mm) at 40C column temperature. All
samples were centrifuged at 15 000 rpm for 5 min at 5C to
precipitate proteins and 3.5 L of the supernatant was sub-
sequently analyzed using the UPLC-DAD system. A gradient
was applied consisting of nanopure water containing 0.1%
TFA (eluent A) and acetonitrile (eluent B) with a flow rate of
0.6 mL/min with the following profile: 0–25% B (0–1.0 min),
25% B (1.0–3.0 min), 25–50% B (3.0–4.0 min), 50–80% B
(4.0–4.5 min), 80% B (4.5–5.5 min), 80–0% B (5.5–6.0 min),
and 0% B (6.0–8.0 min).
The diglucuronide, H-3′7diG, formed by glucuronidation
of either H-7G orH-3′G was identified by comparing its UV
spectrum and retention time with those of commercially
available H-3′7diG. The nature of the sulfate metabolite of
H-7G and H-3′G was confirmed by treating the untermi-
nated incubation samples with -glucuronidase/sulfatase as
there was no commercially reference compound available.
To this end, 50 L of unterminated incubation samples were
added to 50 L of 0.1 M sodium acetate (pH 5.0) containing
189 units/mL -glucuronidase and 1 unit/mL sulfatase. The
reactions were carried out for 3 h at 37C andwere terminated
by adding 25 L of ice-cold acetonitrile.
All formed metabolites were quantified by integrating the
peak area at 280 nm and by using a calibration curve of
H-3′7diG. The sulfate metabolites of H-7G and H-3′G were
quantified based on the calibration curve of H-3′7diG, which
was considered adequate because the sulfate metabolites of
H-7G and H-3′G appeared to have the same UV-spectrum
as H-3′7diG (Supporting Information) and were assumed to
display a similar molar extinction coefficient.
The kinetic parameters including the apparent maximum
velocity (Vmax(app)) and apparent Michaelis–Menten constant
(Km(app)) for different conjugation reactions were determined
by fitting the data to the standardMichaelis–Menten equation
with GraphPad Prism version 5.04 (GraphPad Software, San
Diego, CA, USA). The Michaelis–Menten equation was as
follows:
v = Vmax ∗ [S] / (Km + [S]) (1)
where [S] represents the substrate concentration. The values
of Vmax and Km were expressed in nmol/min/mg protein and
M, respectively.
2.4 Protein kinase A inhibition assay
A protein kinase A (PKA) inhibition assay was carried to
measure the potency of hesperetin and itsmonoglucuronides
H-7G and H-3′G to inhibit PKA as possible mechanism un-
derlying some of its beneficial effects [22,23]. The PKA inhibi-
tion assay was carried out based on the method described by
Chen et al. [24] with somemodifications. The incubationmix-
tures (final volume 50 L) contained (final concentrations)
5 mM MgCl2, 0.5 mM DTT, 96 ng/mL PKA, 4 M kemptide
(PKA substrate), hesperetin, H-7G, or H-3′G added from a
100 times concentrated stock in DMSO (final concentration
ranging from 0 to 500 M) in 50 mM Tris-HCl (pH 7.4).
The final concentration of DMSO was kept at 1% for all incu-
bations. The positive control for PKA inhibition was carried
out using 10 M staurosporine (final concentration), a po-
tent protein kinase inhibitor with a reported IC50 value of
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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0.015 M [25]. The concentration of the substrate kemptide
was selected to be close to theKm value of 4.3Mat 5MATP
for ADP induction (data not shown). The incubationmixtures
were preincubated for 3 min at 30C prior to initiation of the
reactions by adding 5 M ATP (final concentration). After
30min, the reactions were terminated by adding 50 L of ice-
cold ACN. Under the specified conditions, ADP formation
was linear with time and protein content (data not shown).
All samples were centrifuged at 15 000 rpm for 5 min at
5C to precipitate proteins and 5 L of the supernatants were
subsequently analyzed on a UPLC-DAD system consisting of
aWaters (Milford,MA) Acquity binary solventmanager, sam-
ple manager, and photodiode array detector, equipped with
a Waters Acquity UPLC BEH Amide column (1.7 m, 2.1 ×
100 mm) at 30C column temperature. ADP, a by-product
from the phosphorylation reactions, was measured at iso-
cratic conditions (70:30–acetonitrile:27 mM KH2PO4 in
nanopure water pH 4.5) for 8 min and at a flow rate of
0.5mL/min.With thismethod, ADP eluted at 2.02min based
on the retention time andUV spectrumof commercially avail-
able ADP. Triplicate experiments were performed. The in-
hibitory potency of hesperetin and its monoglucuronides was
determined based on comparison to the kinase activity in a
blank incubation performed without added inhibitor contain-
ing 1% DMSO. The obtained concentration–response curves
were translated to in vivo dose–response curve (Section 2.6)
2.5 PBK model
A PBK model for dietary hesperidin was developed in a sim-
ilar manner as previously described for the development of
a PBK model for quercetin [26, 27]. The PBK model was de-
fined to gain more insight in the ADME characteristics of
hesperidin and the various metabolites formed in humans
and to provide a method for conversion of in vitro effective
concentrations to in vivo dose levels (Section 2.6). The model
consisted of separate compartments for gastrointestinal (GI)
tract lumen, small intestine, colon, liver, kidney, rapidly per-
fused tissues (e.g. heart, lung, brain), and slowly perfused
tissues (e.g. skin, muscle, bone) as shown in Fig. 2A and B
for the mono- and diconjugates of hesperetin. Hesperidin
was modeled to be hydrolyzed to its aglycone, hesperetin, by
microbiota in the colon prior to absorption. The rate constants
for hydrolytic clearance of hesperidin by the colonic micro-
biota, for excretion via urine or bile, and for the intestinal
efflux back to the intestinal lumen were obtained by fitting
with available experimental human data [13, 15, 16, 28–30],
resulting in values of 0.1 L/h, 30 h−1, 30 h−1, and 0.2 L/h, re-
spectively. The hesperetin that is released within the lumen
was modeled to be absorbed into the colonic enterocyte by
passive diffusion. The absorption rate constant for intestinal
uptake of hesperetin is not available. An in situ intestinal per-
fusion study showed that the rate transfer of hesperetin to the
intestinal wall was similar to that for genistein [31]. Based on
this observation, the absorption rate constant of hesperetin
was assumed to be similar to that for genistein with a value
of 5 h−1 [32]. To take the transit time of hesperidin from the
stomach to the colon into account, the GI transit rates were
included using the values reported by Kimura et al. [33] of
4.63, 2.44, and 2.76 h−1 for stomach, jejunum, and ileum,
respectively.
Hesperetin was modeled to primarily converse via glu-
curonidation and sulfation forming four different monocon-
jugates at the 3′- and 7-position in small intestine, colon, and
liver. Further conjugation of different monoconjugates to di-
conjugates was simulated only for the mono-glucuronides,
H-7GandH-3′G, since thesemetaboliteswere estimated to be
themajor primarymetabolites formed accounting for approx-
imately 70% of the hesperidin dose based on model stimula-
tion (data not shown). The kinetic constants for formation of
monoconjugates of hesperetin in small intestine, colon, and
liver were taken from the study of Brand et al. [19] (Section
3.2). The kinetic constants for further conjugations of H-7G
and H-3′G via glucuronidation and sulfation were obtained
in the present study from in vitro incubations with relevant
human tissue fractions (Section 3.1–3.2). The Vmax values for
formation of different mono- and diconjugates were scaled
to in vivo Vmax values using a small intestine protein yield of
20.6 mg microsomal protein and 18 mg cytosolic protein [34]
and a liver protein yield of 40 mg microsomal protein and
80.7 mg cytosolic protein [35]. The scaling factors for colonic
metabolism were calculated based on the methods described
by van de Kerkhof et al. [36] using the reported data that
the colonic tissue of male F344 rat with 24 mg wet weight
contained 3 mg protein [37]. A microsomal protein yield of
2.4 mg and a cytosol protein yield of 16.4 mg were calculated
and used as scaling factors for colonic metabolism.
The physiological parameters for humans were obtained
from literature [38] and are shown in Table 1 in the Sup-
porting Information. The tissue:blood partition coefficients
of hesperetin and its metabolites were estimated from log
Kow according to the method described by DeJongh et al. [39]
and are shown in Table 2 in the Supporting Information. Log
Kow values were estimated from Clog P values obtained from
Scifinder (American Chemical Society, USA) and ChemBio-
DrawUltra 14.0 (Cambridge-Soft, USA). Conversion of blood
concentrations of hesperetin and its metabolites to plasma
concentrations was done by dividing the blood concentra-
tions by a blood/plasma ratio (R). This value was calculated
using the Simcyp prediction tool [40, 41] and amounted to
0.66. Mass balance equations were numerically integrated
in Berkeley Madonna version 8.3.18 (Macey and Oster, UC
Berkeley, CA) using Rosenbrock’s algorithm for stiff system.
Mass balance equations for hesperetin and its metabolites
were similar to those previously described by Boonpawa et al.
[26, 27] for PBK models of quercetin. Model performance
was evaluated by comparing the predicted concentrations of
urinary profiles to reported data in human urine [1, 13, 42].
Further evaluation was done by performing a sensitivity anal-
ysis to assess key parameters that contribute substantially to
the maximum concentration (Cmax) of hesperetin aglycone
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 2. PBK model structure for formation of (A)
mono- and (B) diconjugates of hesperetin: KTi =
transit rate constant for stomach (st), jejunum (je),
and ileum (il), hesperetin-7-O-glucuronide (H-7G),
hesperetin-3′-O-glucuronide (H-3′G), hesperetin-7-
O-sulfate (H-7S), hesperetin-3′-O-sulfate (H-3′S),
hesperetin-3′,7-O-diglucuronide (H-diG), and hesper
etin-O-monoglucuronide-O-monosulfate (H-GS).
and its metabolites in plasma at an oral dose of 2.8 and
29 mg/kg bw hesperidin representing the lowest and the
highest hesperidin intake from Western diet and food sup-
plements [17, 18]. Normalized sensitivity coefficients (SCs)
were calculated for the model parameters according to the
method described by Evens and Andersen as follows [43]:
SC = (C ′ − C) / (P ′ − P) × (P/C) (2)
where C is the initial value of the model output, C′ is the
modified value of themodel output resulting froman increase
in parameter value, P is the initial parameter value and P′ is
the modified parameter value, taking a 5% increase in its
value.
2.6 Translation of in vitro effect concentrations to in
vivo dose levels
PBK-based reverse dosimetry was carried out to convert in
vitro effect concentrations to predicted in vivo dose levels of
hesperidin based on the methods described by Louisse et al.
[44] and Strikwold et al. [45]. To this end, biological effects
of hesperetin and its metabolites derived from in vitro bioas-
says were used including inhibition of PKA activity by hes-
peretin and its monoglucuronides (Section 3.5) and available
in vitro literature data for biological effects of hesperetin and
its monoconjugates on inhibition of cell migration induced
by TNF- in human aortic endothelial cells [46] and inhibition
by hesperetin metabolite mixtures (mainly monoconjugates)
on prostaglandin E2 (PGE2) and nitric oxide (NO) production
induced by LPS in RAW 264.7 cells [9]. These in vitro data
also showed that not only hesperetin aglycone, but also its
metabolites could exert similar biological effects with compa-
rable potency, indicating that in vivo effects of hesperidinmay
be due to a mixture of hesperetin aglycone and its metabo-
lites rather than an individual compound. Therefore, the in
vitro effect concentrations obtained for hesperetin and its
metabolites for the respective effects were added up to ob-
tain the in vitro mixture effect concentrations by using the
concept of concentration addition as follows [47]:
ECxmix =
(
n∑
i=1
pi
ECxi
)−1
(3)
where ECxmix is the total concentration of the mixture (in
mg hesperetin equivalents/L) required to produce effect x,
n is the number of mixture components, pi is the relative
fraction of chemical i in the mixture, and ECxi is the con-
centration of i that produces effect x by itself. The pi values
of hesperetin, H-3′G, H-7G, hesperetin-3′-O-sulfate (H-3′S),
and hesperetin-7-O-sulfate in total plasma concentrations of
hesperetin (aglycone and metabolites) were predicted to be
0.01, 0.54, 0.32, 0.08, and 0.05 based on model stimulation
(data not shown).
Before making the in vitro to in vivo translation, it is of
importance to realise that hesperidin will bind to protein and
lipid [48] and only the free fraction (fu) of the chemical will
exert the effects, which implies a correction is required for dif-
ferences between protein (predominantly albumin) and lipid
(predominantly triglycerides, cholesterol, cholesterol ester,
and phospholipid) binding in the in vitro bioassays and the
in vivo situation. For the PKA inhibition activity that was per-
formed using bioassay conditions without added protein and
lipid, each nominal in vitro effect concentration (ECin vitro) was
extrapolated to an in vivo effective concentration (ECin vivo) by
dividing the ECin vitro with the fuin vivo assuming 100% avail-
ability in vitro. The average fuin vivo of 0.27 forH-7G andH-3′G
was used as approximately 70% of the total plasma hesperetin
concentration (aglycone and metabolites) was predicted to be
H-7G and H-3′G (Table 2 in the Supporting Information and
Section 3.4). For in vitro activities that were obtained from in
vitro bioassays performed in the presence of culture medium
with added protein and lipid, each ECin vitro was extrapolated
to an ECin vivo according to the extrapolation rule of Gu¨lden
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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and Seibert as follows [49]:
ECin vivo = ECin vitro
×
[
(1 − f bin vitro) × 1 + KOW × V
′
L,serum
1 + KOW × V′L,in vitro
+ f bin vitro × PserumPin vitro
]
(4)
where fbin vitro is the fraction of chemical bound to protein and
lipid in culture medium, which is calculated from 1 – fuin vitro.
V′L is the lipid fraction in serum and in vitro. P is the protein
content in serum and culture medium.
For the extrapolation, in vivo albumin and lipid concen-
trations of 600 M and 6 g/L were used [49]. The albumin
and lipid concentrations in culture medium of the reported
in vitro bioassays were estimated from the reported data by
Gu¨lden et al. [50] indicating that 5% foetal bovine serum con-
tains 18 M bovine serum albumin and 0.1 g/L lipid. The
fuin vitro values of hesperetin and its metabolites in in vitro
medium were estimated using the reported binding constant
of hesperetin, H-7G, and H-3′G to human serum albumin
of 8, 4, and 6 × 104 M−1 [48] and a binding site number of
1.05 [51], assuming a similar binding constant for human
and bovine serum albumin. This assumption is based on the
fact that genistein has been reported to have a similar bind-
ing constant for bovine and human serum albumin [52]. The
in vivo effect concentration of the mixtures obtained after
correction for difference in protein and lipid between the in
vitro and in vivo situation was set equal to plasma Cmax of
the mixtures in the PBK model to predict the correspond-
ing oral dose level in humans. The 95% lower and upper
confidence limit of the in vivo dose–response curves were
estimated from the derived in vivo dose–response curve us-
ing GraphPad Prism version 5.04 (GraphPad Software). The
data points of the derived 95% lower and upper confidence
limit in vivo dose–response curves were digitized using Plot
Digitizer version 2.5.1 (Joseph A. Huwaldt, Sourceforge.net).
Subsequently, the digitized data thus obtained were used to
estimate the benchmark dose for 5% response (BMD05) based
on the default benchmark response for continuous data [53].
The BMD05 values were estimated by fitting to the Hill model
using Benchmark Dose Software version 2.6 (The Environ-
ment Protection Agency’s, USA). The BMD05 values obtained
were evaluated against reported active human data on an-
tiatherogenic and anti-inflammatory activity upon oral intake
of hesperidin [54–56].
3 Results
3.1 Enzymatic conjugation of H-7G and H-3′G in
incubations with human tissue fractions
Analysis of glucuronidation incubations of H-7G and H-
3′G containing pooled human tissue fractions revealed that
H-7G was further glucuronidated by human small intes-
tine and liver microsomes, revealing one metabolite that is
formed, whereas H-3′G was only further glucuronidated by
human liver microsomes, resulting in the same metabolite
as observed from the incubations with H-7G. This metabolite
coeluted with and showed similar spectral characteristics as
commercially available H-3′7diG and could thus be identified
as H-3′7diG. Under the conditions of the present study, no
glucuronidated metabolites of H-7G or H-3′G were formed
in incubations containing human colon S9.
Analysis of sulfation incubations of H-7G and H-3′G con-
taining pooled human tissue fractions revealed that H-7G
was further sulfated by human small intestine and liver cy-
tosol, while H-3′G was only further sulfated by human small
intestine cytosol. The metabolites formed in the sulfation
incubations with H-7G and H-3′G with a retention time
of 1.3 and 1.4 min were identified by treating the unter-
minated samples with -glucuronidase/sulfatase resulting
in a disappearance of the respect peak and a concomitant
equivalent increase in the peak area of hesperetin aglycone
(data not shown). These results confirm that the metabolites
weremost likely hesperetin -7-O-glucuronide-3′-O-sulfate (H-
7G-3′S) and hesperetin-3′-O-glucuronide-7-O-sulfate because
conjugation of the flavonoid likely occurs at available free
OH moieties [57] and the five position is not available for
conjugation due to intramolecular hydrogen bonding with
the carbonyl group at the C-4 position [58]. Under the condi-
tions of the present study, no sulfated metabolites of H-7G
and H-3′G formed in incubations with human colon S9 were
detected.
3.2 Kinetic constants for formation of mono- and
diconjugates of hesperetin
The concentration-dependent rates of glucuronidation and
sulfation of H-7G and H-3′G by human tissue fractions are
shown in Fig. 1 in the Supporting Information. The kinetic
constants derived from these results and the kinetic constants
for formation of different hesperetin monoconjugates ob-
tained from Brand et al. [19] are summarized in Table 1.
The results indicate that small intestine and liver had sim-
ilar catalytic efficiency for metabolism of hesperetin with
the total catalytic efficiency amounting to approximately 2.5
L/h/g tissue for both tissues, followed by colon with a to-
tal catalytic efficiency of 0.17 L/h/g tissue. Small intestine
and liver tissues showed a difference in the type of conjuga-
tion of hesperetin as small intestine appeared to be especially
effective in formation of H-3′S, whereas liver was more ef-
fective in converting hesperetin into H-3′G. The formation
of diconjugates was more than 100-fold less efficient than
the formation of the respective monoconjugates due to a de-
crease in Vmax and an increase in Km values. Colon could only
covert hesperetin to monoconjugates as there was no forma-
tion of diconjugates detected in incubations with this tissue
fraction.
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3.3 PBK model development and evaluation
The PBK model for hesperidin consisted of separate com-
partments for GI tract lumen, small intestine, colon, liver,
kidney, and blood, which are the major organs involved in
ADME of hesperidin and its metabolites (Fig. 2A and B). The
remaining organs are lumped to either rapidly perfused tis-
sues (e.g. heart, lung, brain) or slowly perfused tissues (e.g.
skin, muscle, bone). To define the PBKmodel, kinetic param-
eters for formation of different hesperetin mono- and dicon-
jugates were obtained from in vitro incubations. While the
hydrolytic clearance of hesperidin by gut microbiota and the
kinetic parameters for excretion via urine, bile, and intestinal
efflux back to intestinal lumen were obtained by fitting the
predicted dose-dependent plasma concentrations of total hes-
peretin concentrations with available experimental human
data in plasma [13,15,16,28–30], resulting in values of 0.1 L/h,
30 h−1, 30 h−1, and 0.2 L/h, respectively. Subsequently, the
model thus defined was used to predict the total hesperetin
plasma kinetics as shown in Fig. 3. Twenty-four out of 30
predictions on plasma Cmax, area under the time–response
curve, and Tmax of total hesperetin were within twofold devia-
tion from the reported human data [13,15,16,28–30], whereas
the rest of the predictions were within three- to sixfold devi-
ation. The reason for this discrepancy might be due to in-
terindividual human variation in metabolism of hesperetin,
especially for the parameters of influence that were defined
by the sensitivity analysis.
The performance of the defined PBKmodel was evaluated
to a further extent by comparing the predicted concentrations
of hesperetin metabolites excreted in urine to the reported
literature data for hesperetin metabolites in human urine
[1,13,42]. Figure 4 shows the results of this comparison reveal-
ing that the model adequately predicted the urinary profiles
of different mono- and diconjugates of hesperetin as 20 of 27
of the predicted values for excretion of hesperetinmetabolites
were within twofold deviation from the reported urinary pro-
files of hesperetin metabolites in humans [1,13,42], whereas
the others were within four- to sevenfold deviation. The rea-
son for this discrepancy might be due to interindividual hu-
man variation in metabolism of hesperetin, especially for the
parameters of influence that were defined by the sensitivity
analysis.
To further evaluate the performance of the definedmodel,
a sensitivity analysis was performed to assess key parameters
that influence the predicted plasma Cmax of hesperetin agly-
cone and its metabolites at an oral dose of 2.8 and 29 mg/kg
bw hesperidin representing the lowest and the highest hes-
peridin intake originating from the Western diet and from
food supplements, respectively [17,18]. Only parameters that
had a normalized SC higher than 0.1 (in absolute value) are
shown in Fig. 2 in the Supporting Information. The results
reveal that the normalized SCs of most of the PBK model
parameters were not dose dependent. The predicted plasma
Cmax of hesperetin aglycone and its metabolites are mainly
influenced by the body weight, the volume of the GI tract
Figure 3. Observed and PBK model-predicted (A) plasma Cmax,
(B) plasma area under the time–response curve (AUC), and (C)
plasma Tmax of total hesperetin (aglycone and metabolites) in
humans at different dose levels as indicated by the x-axis labels
[13, 15, 16, 28–30]. Data sets presented represent dose regimens
for which observed values were reported in the literature.
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 4. Model evaluation by comparing the PBK
model-predicted urinary profiles with those reported by
(A) Mullen et al. at 0.73 mg/kg bw hesperidin [13], (B)
Bredsdorff et al. at 0.93 mg/kg bw hesperidin [42], (C)
Bredsdorff et al. at 2.92mg/kg bwhesperidin [42], and (D)
Pereira-Caro et al. at 2.87 mg/kg bw hesperidin [1]. Data
sets presented represent dose regimens for which ob-
served values were reported in the literature. Since the
literature study reporting observed levels for H-GS did
not discriminate between hesperetin-3′-O-glucuronide-
7-O-sulfate (H-3′G-7S) and H-7G-3′S, H-GS represents
both conjugates.
lumen and liver, the reginal blood flow through the small
intestine and colon, the blood to plasma ratio, and the biliary
excretion (expressing normalized SCs between 0.5 and 2.6
in absolute value). The parameters that influenced the for-
mation of hesperetin monoconjugates in the colon and liver,
including the microsomal and cytosol protein contents in the
colon and liver and the kinetic constants for formation of
monoconjugates, are also influential parameters for the pre-
dicted plasmaCmax of hesperetin aglycone and itsmetabolites
(expressing normalized SCs between 0.2 and 0.9 in absolute
value). In addition, the kinetic constants for formation of H-
3′7diG and H-7G-3′S in the liver and the kinetic constants
for formation of hesperetin-3′-O-glucuronide-7-O-sulfate and
the cytosol protein content in the small intestine are also
influential parameters for the predicted plasma Cmax of its
respective diconjugates (expressing normalized SCs between
0.3 and 2.0 in absolute value).
3.4 PBK model predictions of metabolic plasma
profiles of hesperidin
The PBKmodel was used to predictmetabolic plasma profiles
of hesperidin at different dose levels. Figure 5 shows the pre-
dicted dose-dependent plasma concentrations of hesperetin
aglycone and its metabolites (expressed in mg hesperetin
equivalents/L) at oral doses ranging from 0.01 to 50 mg/kg
bw hesperidin, revealing that the conjugation pattern of the
circulating metabolites does not change with the dose. At all
oral doses,H-3′GandH-7Gwere predicted to be themajor cir-
culating metabolites together accounting for approximately
70% of the total plasma hesperetin concentration (aglycone
and metabolites), followed by H-7G-3′S, H-3′S, and H-3′7diG
accounting for approximately 15, 6, and 4%of the total plasma
hesperetin concentration, respectively. Hesperetin aglycone
was present at a low concentration below 0.02 mg/L at a dose
of 50 mg/kg bw and accounted for approximately 0.5% of the
total plasma hesperetin concentration at all oral doses.
Figure 5. PBK model based prediction of the dose-dependent
plasma Cmax of hesperetin aglycone and its metabolites at oral
doses ranging from 0.01 to 50 mg/kg bw hesperidin: hesperetin
(H), glucuronide (G), and sulfate (S).
3.5 Translation of in vitro effect concentrations to in
vivo effective dose levels in human
In the next step, the PBKmodel was used for reverse dosime-
try converting in vitro effective concentrations to in vivo effec-
tive dose levels of hesperidin for selected endpoints. To this
end, in vitro concentration–response curves were defined in
first instance for PKA inhibition by hesperetin, H-3′G, and
H-7G in the present study. The results obtained reveal that
hesperetin and also its major circulating metabolites, H-3′G,
and H-7G, all inhibit PKA activity in vitro in a concentration-
dependent manner as shown in the left panel of Fig. 6A.
This figure, reflecting the in vitro concentration–response
curves for PKA inhibition by hesperetin, H-3′G, and H-7G
(left panel of Fig. 6A), also depicts as a first approximation
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 6. Translation of in vitro concentration–response
curves for (A) inhibition of PKA activity (present study), (B)
inhibition of endothelial cell migration [46], (C) inhibition
of LPS-induced prostaglandin E2 (PGE2) production [9], and
(D) inhibition of LPS-induced nitric oxide (NO) production
[9] to human hesperidin dose–response curves using PBK
model based reverse dosimetry based on plasma Cmax of
total hesperetin (aglycone and metabolites). For inhibition
of LPS-induced PGE2 and NO production, in vitro studies
for these endpoints were carried out with mixtures of hes-
peretin metabolites, not individual metabolites, and thus
only the mixtures concentration–response curves are pre-
sented (C and D left panel) [9].
the concentration–response curves for PKA inhibition by
combined exposure to the mixtures of hesperetin, H-3′G,
and H-7G, assuming the three compounds to be present
at the ratios predicted to be present in plasma, and using
the concentration–response curves for the individual com-
pounds, expressing the concentration of the mixture in mg
hesperetin equivalents/L. Figure 6B–D (left panels) presents
similar in vitro data for the effect of hesperetin and its con-
jugates on other endpoints including effects on inhibition
of cell migration induced by TNF- (Fig. 6B left panel), in-
hibition of PGE2 production induced by LPS (Fig. 6C left
panel), and inhibition of NO production induced by LPS (Fig.
6D left panel). The latter two Figs 6(6C and D left panel)
only present the in vitro concentration–response curves for
the mixtures (mainly monoconjugates) as in vitro studies for
these endpoints were carried out with mixtures of hesperetin
metabolites obtained fromrat plasma exposed to 50mg/kgbw
hesperetin [9]. The major circulating metabolites of hes-
peretin in rat exposed to 50 mg/kg bw hesperidin were re-
ported to be monoglucuronides followed by mixed conju-
gates containing glucuronic acid and sulfate moieties [59],
which is comparable to the predicted metabolic plasma pro-
files in humans (Section 3.4). In a subsequent step, these
in vitro concentration–response curves were translated into
in vivo dose–response curves using a PBK model based re-
verse dosimetry. To this end, each in vitro mixture con-
centration was extrapolated to an in vivo mixtures concen-
tration in plasma by taking into account the differences
in protein and lipid concentration between the in vitro
bioassays and the in vivo situations (see Section 2.6). The
plasma in vivo concentrations of the mixtures of hesperetin
and its metabolites thus obtained were used as input in
the PBK model to predict the in vivo dose levels of hes-
peridin required to achieve these plasma concentrations,
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deriving the in vivo dose–response curve. Figure 6 (right
panels) depicts the in vivo dose–response curves obtained.
The figures also present the 95% lower and upper confidence
limits of the predicted in vivo dose–response curves. Subse-
quently, the obtained in vivo dose–response curves were used
to estimate the BMD05 values for the respective biological ef-
fect of hesperidin in humans. In this way, the BMD05 values
for several biological effects including inhibition of PKA, in-
hibition of cell migration induced by TNF-, inhibition of
PGE2 production induced by LPS, and inhibition of NO pro-
duction induced by LPS were predicted using a PBK model
based reverse dosimetry.
Figure 7 shows the predicted in vivo BMD05 values based
on in vitro data for the inhibition of PKA activity by hesperetin
and its metabolites, endothelial cell migration, and induction
of PGE2 and NO. The in vivo BMD05 values for PKA inhibi-
tion were predicted to occur at oral doses ranging from 135 to
539 mg/kg bw hesperidin. The in vivo BMD05 values for in-
hibition of endothelial cell migration were predicted to occur
at oral doses ranging from 4.54 to 24 mg/kg bw hesperidin.
The in vivo BMD05 values for inhibition of PGE2 production
were predicted to occur at oral doses ranging from 2.19 to
4.10 mg/kg bw hesperidin. And the in vivo BMD05 values for
inhibition of NO production were predicted to occur at oral
doses ranging from 17 to 44 mg/kg bw hesperidin.
The predicted in vivo BMD05 values for effects of hes-
peretin and its metabolites on PKA activity, endothelial cell
migration, PGE2 production, andNOproduction based on the
in vitro PBK approach were evaluated by comparing the pre-
dicted in vivo BMD05 values with the reported active dose lev-
els of hesperidin on anti-atherogenic and anti-inflammatory
effects in healthy humans [54–56] as PKA regulates several
cellular functions [23], endothelial cell migration is an initi-
ated bioprocess for atherosclerosis [46], and PGE2 andNO are
inflammatory biomarkers [9]. The results as shown in Fig. 7
reveal that the predicted in vivo BMD05 values for inhibition
of endothelial cell migration and PGE2 production are in line
with the active dose levels of hesperidin (4.2 mg/kg bw) in
human intervention studies reported to result in improved
endothelial function and decreased levels of inflammatory
biomarkers (i.e. PGE2 and C-reactive protein) [54–56]. The
predicted in vivo BMD05 values for inhibition of NO produc-
tion are four to tenfold higher than the reported active dose
levels of hesperidin in humans [54–56]. In the case of PKA
activity, the predicted in vivo BMD05 values are more than
32-fold higher than the reported active dose levels of hes-
peridin on anti-atherogenic and anti-inflammatory effects of
hesperidin in humans [54–56].
ThePBKmodel basedpredicted dose–response curves and
in vivo BMD05 values derived from them also indicate that at
a Western dietary and a supplementary intake of hesperidin
amounting to 2.8–8 and 7–29 mg/kg bw, respetively [17, 18],
the plasma Cmax of total hesperetin would be high enough to
inhibit endothelial cell migration, PGE2 production, and NO
production (Fig. 7).
4 Discussion
The aim of the present study was to develop a PBK model
describing the ADME of hesperidin in humans to obtain in-
sight in dose-dependent plasma concentrations of hesperetin
aglycone and its circulating metabolites and to subsequently
combine the developed PBK model with in vitro effect con-
centrations to determine whether and if so at what oral dose
levels the in vitro effects of hesperetin and its metabolites
may actually occur in vivo. Evaluation of the PBK model de-
veloped against literature reported data on plasma kinetics
and urinary profiles of hesperidin reveals that the model ade-
quately predicted plasma kinetics of total hesperetin and uri-
nary profiles of hesperidin within one- to sevenfold deviation.
Themodel developed was used to predict the dose-dependent
plasma concentrations of hesperetin aglycone as well as the
type of circulating metabolites. The results revealed that the
metabolic plasma profiles of hesperidin appear independent
of the dose because similar circulating metabolite patterns of
hesperetin were predicted at all dose levels from 0.01 to 50
mg/kg bw hesperidin. The model predicted that H-3′G and
H-7G were the major circulating metabolites of hesperidin
and that the plasma concentrations of hesperetin aglycone
were limited and predicted to be lower than 0.02 mg/L even
at an oral dose of 50mg/kg bwhesperidin. This implies that in
vivo effects of hesperidin would probably have to be at least in
part ascribed to hesperetin metabolites including H-3′G and
H-7G.
Given that hesperidin was predicted to be present in
the systemic circulation mainly in the form of conjugated
metabolites, it is crucial to understand the biological activity
of these conjugates in order to gain more insight in possible
in vivo effects of hesperidin. The in vitro data on PKA in-
hibition of hesperetin and its major circulating metabolites
H-3′G and H-7G showed that the two metabolites were at
least equally active in inhibition of PKA as hespertin agly-
cone. Yang et al. reported that at the same concentration mix-
tures of hesperetin metabolites (mainly monoconjugates) ex-
hibited approximately twofold higher inhibition of PGE2 and
NOproduction as comparedwith hesperetin aglycone in LPS-
stimulated RAW 264.7 [9]. Hesperetin monoconjugates were
also reported to exert inhibition activity on cell migration in
TNF- treated human aortic endothelial cell with approxi-
mately 1.5-fold lower potency than hesperetin aglycone at the
same concentration [46]. Overall, this points out that conju-
gation does not necessary result in loss or reduction of the
biological activity and in vivo effects of hesperidin are at least
in part due to its metabolites. Based on these results it was
decided that in a first approximation the concentrations of
hesperetin and its metabolites could be added up for evalu-
ation of how the in vitro effect concentrations translate into
the in vivo hesperidin dose level.
The PBK model developed provided a unique tool to gain
more insight in how the in vitro concentrations translate into
in vivo dose levels of hesperidin by applying PBKmodel based
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Figure 7. Comparison of the
predicted in vivo BMD05 values
of hesperidin derived from in
vitro effects of the mixtures of
hesperetin and its metabolites
on inhibition of PKA activity
(present study), endothelial cell
migration [46], prostaglandin E2
(PGE2) production [9], and nitric
oxide (NO) production [9] with
the reported active dose lev-
els on anti-atherogenic and anti-
inflammatory effects of hes-
peridin in humans [54–56] and
with a Western dietary [17] and
a supplementary [18] intake of
hesperidin.
reverse dosimetry. The in vivo dose–response curves obtained
were used to derive the BMD05 values at which plasma con-
centrations of hesperetin together with its metabolites would
be high enough to exert 5% response for inhibition of PKA
activity, inhibition of TNF- induced endothelial cell migra-
tion, inhibition of LPS induced PGE2 production, and inhi-
bition of LPS-induced NO production. The predicted in vivo
BMD05 values for PKA inhibition ranged from 135 to 539
mg/kg bw hesperidin. The predicted in vivo BMD05 values
for inhibition of TNF--induced endothelial cell migration
ranged from 4.54 to 24 mg/kg bw hesperidin. The predicted
in vivo BMD05 values for inhibition of LPS-induced PGE2
production ranged from 2.19 to 4.10 mg/kg bw hesperidin.
And in the case of LPS-induced NO production, the in vivo
BMD05 values for inhibition ranged from 17 to 44 mg/kg
bw hesperidin. These predictions were evaluated against the
reported active dose levels of hesperidin for anti-atherogenic
and anti-inflammatory effect as reported in humans [54–56].
The predicted in vivo BMD05 values for inhibition of endothe-
lial cell migration and PGE2 production are in line with the
reported active dose levels of hesperidin in humans for im-
proving endothelial function and decreasing levels of inflam-
matory biomarkers (i.e. PGE2 and C-reactive protein) [54–56].
The predicted in vivo BMD05 values for inhibition of NO pro-
duction are four- to tenfold higher than the reported active
dose levels of hesperidin in humans [54–56]. The predicted
in vivo BMD05 values for PKA inhibition are more than
32-fold higher than the reported active dose levels for anti-
atherogenic and anti-inflammatory effects of hesperidin in
humans [54–56]. This might imply that inhibition of PKA ac-
tivity (a regulator of several cellular functions [23]) is not ama-
jor mechanism for anti-atherogenic and anti-inflammatory
action of hesperidin in vivo.
Based on the predicted in vivo BMD05 values for hes-
peridin derived from in vitro concentration–response curves
for hesperidin-mediated inhibition of PKA activity, TNF-
induced endothelial cell migration, and LPS-induced produc-
tion of PGE2 andNO, it can also be concluded that the plasma
Cmax of total hesperetin (aglycone and metabolites) at a West-
ern dietary and a supplementary intake amounting to 2.8–8
[17] and 7–29 [18]mg/kgbwhesperidinwould behigh enough
to induce these effects on endothelial cell migration and
pro-inflammatory molecules in vivo. For the inhibition of
PKA activity, the plasma Cmax of total hesperetin upon these
dietary or supplementary intakes would generally not be high
enough to induce a similar effect on PKA activity in vivo.
Overall, the PBK model developed in the present study
adequately predicted ADME of hesperidin in humans. The
model obtained was also shown to be of use to translate in
vitro results on the biological effects of hesperetin aglycone
and its metabolites to the human in vivo situation and evalu-
ate the possible occurrence of in vivo effects without the need
for human intervention studies.
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